Chong Kun Dang Receives UK Approval for Phase 1 Clinical Trial of Dyslipidemia Treatment

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang announced on the 15th that its dyslipidemia treatment drug ‘CKD-508’ has received approval for Phase 1 clinical trials from the UK regulatory authority (MHRA).

CKD-508 is a dyslipidemia treatment drug that lowers low-density lipoprotein cholesterol (LDL-C) and raises high-density lipoprotein cholesterol (HDL-C) by inhibiting the activity of cholesterol ester transfer protein (CETP), which promotes the transport of cholesterol esters (CE) and triglycerides (TG) among lipoproteins in the blood.

Chong Kun Dang stated, "In efficacy evaluation experiments using dyslipidemia animal models, CKD-508 showed excellent lipid improvement effects by significantly reducing LDL-C and apolipoprotein (Apo-B) contained in LDL-C, while increasing HDL-C."

In particular, unlike existing CETP inhibitors such as anacetrapib or torcetrapib, whose development was halted due to safety issues, CKD-508 was found not to cause problems such as drug accumulation in adipose tissue or increased blood pressure, the company explained.

The global market size for dyslipidemia currently stands at $6 billion and is expected to expand to $14 billion by 2027.

Based on preclinical results, Chong Kun Dang plans to confirm the drug’s safety and lipid-improving effects in Phase 1 clinical trials to be conducted in Europe.

A Chong Kun Dang official said, “CKD-508 is an innovative drug that can offer another treatment option for dyslipidemia patients not controlled by statins, and it is expected to have potential as a global new drug.”

This content was produced with the assistance of AI translation services.